Immunotherapy and kidney cancer care

Dr Michael AtkinsHas Immune Checkpoint blockade re-established immunotherapy as a Key Pillar of Kidney cancer care?

Want to know what’s new in immuno-oncology for kidney cancer, and what it means for clinicians, patients, and caregivers? A unique live educational event took place in San Francisco on Friday, January 8, 2016, during the American Society of Clinical Oncology’s Genitourinary Cancers Symposium. Together with our chair Dr. Michael B. Atkins, clinical faculty Dr. Robert J. Motzer and Dr. Brian I. Rini, and patient advocate Deborah Maskens, we organized a stimulating learning session to give the audience an opportunity to learn where we currently stand with immune checkpoint blockade in renal cell carcinoma and what we can expect moving forward, hear about interesting case scenarios, and get answers to their most burning questions about immuno-oncology.

Even though this event happened in January, you can still register for this CME event on the activity website: http://bit.ly/GU16RCC. You will be notified as soon as the onDemand multimedia activity is available online.

Dr. Michael Atkins